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Summary 
It has been 7 years since the National Health and Medical Research Council altered its 
guidelines on how women with a low-grade Pap test result or a treated high-grade cervical 
biopsy result should be managed. 
This report looks at the evidence that the Safety Monitoring Committee collected to evaluate 
effects of this change. This Committee was established to assess whether there were adverse 
outcomes following the introduction of the new guidelines. 
Based on its assessment of the evidence, the Committee determined that: 
• the change in management for women with a low-grade Pap test result has not led to an 
increase in cervical cancer 
• women who complete ‘test of cure’ after being treated for a high-grade cervical biopsy 
result have a very low rate of subsequent high-grade biopsy results, and to date none 
have developed cervical cancer 
• limited data were available to audit cancer cases but it appeared that a range of factors 
may have contributed to the cancers that did arise after the detection of cytological 
abnormalities 
• attendance by women for a follow-up test within 3 months of the recommended interval 
is generally high, although based on the evidence, women aged less than 30 are less 
likely to attend within 15 months of their initial low-grade Pap test result than women 
aged over 30  
• attendance has been lower than recommended among women with a recent low-grade 
Pap test result whose first follow-up test was negative, possibly due to women 
considering themselves ‘safer’ after this negative test  
• overall laboratory recommendation codes were broadly concordant with the changed 
management guidelines, although concordance was lower for low-grade management 
exceptions, that is women over 30 and those who had a second low-grade abnormality. 
There is evidence that the use of automated decision support tools in laboratories assists 
them to comply with the new guidelines. 
The projects undertaken under the auspices of the Safety Monitoring Committee contribute 
to a current picture of the safety of the NHMRC Guidelines for the management of screen detected 
abnormalities in asymptomatic women introduced in Australia in July 2006, compared to the 
previous NHMRC Guidelines that were rescinded at that time. 
Acknowledging that new evidence may come to light in future which could affect this 
picture, the overarching message from the evidence currently available and the methods 
used to assess this evidence is that the new guidelines have not led to an increase in cervical 
cancer in the 7 years since they were introduced. 
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1 Introduction 
1.1 Why have guidelines? 
There are over 2 million Papanicolaou smears, or ‘Pap tests’ to detect cervical cell 
abnormalities performed on Australian women each year, with around 110,000 of these 
detecting abnormal cells (AIHW 2013). The detection and management of abnormalities—
particularly ‘high-grade’ abnormalities—is the way in which the National Cervical Screening 
Program (NCSP) prevents the development of cervical cancers, thereby achieving its aim of 
reducing cervical cancer cases, as well as illness and death resulting from cervical cancers. 
Guidelines enable practitioners and clinicians to manage the 110,000 abnormalities 
detected each year according to evidence-based information which guides best practice. 
The National Health and Medical Research Council’s (NHMRC) Screening to prevent cervical 
cancer: Guidelines for the management of asymptomatic women with screen detected abnormalities 
(‘the NHMRC Guidelines’) (NHMRC 2005) provides recommendations for the management 
of women with an abnormal Pap test result. They enable practitioners and clinicians to 
manage these 110,000 abnormalities detected each year according to evidence-based 
information which guides best practice. 
The latest guidelines were approved in June 2005 and implemented from 3 July 2006, and 
replaced the previous 1994 guidelines, which were rescinded. Formulated in line with the 
NHMRC standards for clinical practice guidelines available at that time, these guidelines are 
based on epidemiological and scientific evidence and a new understanding of the role of 
human papillomavirus (HPV) in cervical cancer (DoHA 2012). 
1.2 Why monitor the safety of these guidelines? 
The 2005 NHMRC Guidelines included management recommendations that were 
significantly different to the previous 1994 guidelines. They included: 
• changed recommendations for the management of women with a low-grade squamous 
abnormality (possible or definite low-grade squamous intraepithelial lesion) on cytology, 
with most women with this result recommended to have a repeat Pap test in 12 months 
• a new management approach for women who have been treated for high-grade 
intraepithelial disease, recommending that they now undergo a ‘test of cure’ process, 
whereby cervical cytology and human papillomavirus (HPV) tests are conducted at 12-
month intervals and if both are negative on two consecutive occasions, the woman is 
returned to the usual 2-yearly screening interval. 
As these were significant changes to the way women are managed, in late 2005 a Safety 
Monitoring Committee (SMC) was established to monitor the safety of these 
recommendations and provide timely review of policy as needed. 
Safety Monitoring Committee (SMC) 
The SMC comprises relevant experts, including representatives from the Royal Australian 
College of General Practitioners, the Royal College of Pathologists of Australasia (RCPA), the 
Royal Australian and New Zealand College of Obstetricians and Gynaecologists, the 
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Australian Society for Colposcopy and Cervical Pathology (ASCCP), the Australasian 
Association of Cancer Registries (AACR) and the Australian Institute of Health and Welfare 
(AIHW), as well as a National Cervical Screening Program (NCSP) program manager and 
data manager, a consumer representative, statisticians and epidemiologists, and officers of 
the Department of Health (DoH).  
The SMC reports to the Standing Committee on Screening (formerly the Screening 
Subcommittee) of the Community Care and Population Health Principal Committee 
(formerly the Australian Population Health Development Principal Committee). Both 
Committees were renamed in early 2012. 
Box 1.1: Clinical terminology 
Because the management guidelines are intended for a clinical audience, use of clinical 
terms is unavoidable; the following provides a brief guide to the main clinical terms used. 
Uterine cervix, or simply ‘the cervix’ is the neck of the uterus or ‘womb’. The cervix is 
comprised of squamous cells on the outer part of the cervix and glandular cells in the 
endocervical canal (the ‘transformation zone’ where squamous and glandular cells meet is 
where abnormalities and cancer are usually found). 
Cytology is the examination of cells from the cervix through a microscope. These cells are 
usually collected by a Pap test, which is the screening test of the National Cervical 
Screening Program. 
The terms intraepithelial lesion, intraepithelial disease and abnormality are used 
interchangeably, and all refer to the presence of abnormal cells in the epithelial layers of the 
lining of the uterine cervix. 
Abnormalities are graded depending on how much of the lining of the cervix abnormal cells 
occupy; ‘low-grade’ abnormalities are contained in the top layer of the lining of the cervix, 
while ‘high-grade’ abnormalities occupy more layers. 
1.3 How has the safety of the guidelines been 
monitored? 
The SMC has undertaken several projects to fulfil its role of assessing the safety of the 
guideline recommendations for the management of women with a low-grade cervical 
cytology result and women treated for high-grade intraepithelial disease. 
The primary project, and a modification of the process recommended by the Guidelines 
Review Group outlined in appendices 12 and 13 of the guidelines (NHMRC 2005), has been a 
major statistical analysis that the AIHW performed using cervical cytology register data. This 
was to determine if there has been an increase in the risk of cervical cancer in women 
following a low-grade cervical cytology or treated high-grade histology under the 2005 
guidelines compared to the 1994 guidelines. Results of these analyses were provided to the 
SMC in 6-monthly reports, with each report extending the period of data collection under the 
2005 guidelines by 6 months.  
Supplementing this primary project are a cancer case review of all cervical cancer cases 
diagnosed in women after a low-grade cervical cytology result and in women treated for 
high-grade intraepithelial disease; a laboratory survey; an assessment of laboratory 
compliance with guideline recommendations; and an assessment of national cervical cancer 
incidence data. 
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The SMC assessed these projects in-house for some time in advance of sufficient data being 
available to reach firm conclusions that could be made publicly available. The SMC agreed 
that a ‘warning’ flag would be raised if safety monitoring parameters exceeded expected 
levels at the 10% α-level and an ‘immediate action required’ flag if the parameters exceeded 
expected levels at the 5% α-level. Through this mechanism, important results would be made 
available promptly and immediate action taken if it became apparent that the new guidelines 
were unsafe. 
 
 
Figure 1.1: The projects used by the Safety Monitoring Committee to assess the safety of the new 
NHMRC Guidelines 
Survival analysis 
Cancer case 
review 
Compliance 
Incidence data 
Detection data  
Laboratory 
survey 
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2 Consideration of background trends in 
cervical abnormalities and cancer 
Any trends that may emerge from the projects undertaken under the auspices of the SMC do 
so within a broader cervical screening environment. As such, it is important to consider 
background trends in the prevalence of low-grade and high-grade abnormalities. 
Trends in cervical cancer incidence are also important to consider as part of the safety 
monitoring of the guidelines, since any increase in the incidence of cervical cancer might be a 
direct result of the change in guidelines implemented in 2006. 
This chapter presents the latest data and trends in cervical abnormality detection—sourced 
from state and territory cervical cytology registers, and cervical cancer incidence—sourced 
from the Australian Cancer Database (ACD) and provided by state and territory cancer 
registries. 
Box 2.1: Detection versus incidence 
When considering the detection of abnormalities, it is important to note that, while cervical 
abnormalities are present in a proportion of women in the population at any one time, these 
abnormalities can only be detected if these women have a Pap test. Thus, while data on the 
detection of abnormalities can reflect underlying incidence of abnormalities in the 
population, these data are really conveying how many abnormalities are found through 
cervical screening, and not how many abnormalities are present.  
Incidence, on the other hand, is the true number of cases of disease present in the 
population, and is the terminology used for cervical cancer trends. 
2.1 Cervical abnormalities detected by cytology 
In 2011, there were 115,026 abnormalities (low-grade, high-grade or cancer) detected in the 
2,025,860 cytology tests for women aged 20–69 (5.6 abnormalities per 100 cytology tests). Of 
these abnormalities, 84,540 (73.5%) were low-grade and 30,253 (26.3%) were high-grade, with 
cancer making up the remaining 0.2% (Table 2.1). 
Cytologically detected abnormality trends 
The detection of low-grade abnormalities decreased steadily from a peak of 114,257 in 2005  
to 78,510 in 2010 for women aged 20–69 (this was a decrease from 5.5 to 3.9 per 100 cytology 
tests, age-standardised). A slight increase from 78,510 in 2010 to 84,540 in 2011 (from 3.9 to 
4.1 per 100 cytology tests, age-standardised) was noted but this was still well below the 
detection rate prior to 2006 (Table 2.1). The trend for a decline in low-grade abnormalities 
since 2006 is consistent with the change in guidelines for women with a low-grade cytology 
result, since fewer low-grade cytology tests were repeated under the new guidelines, leading 
to the observed decrease in the detection of low-grades by cytology results. The longer 
interval for repeat smears was directed at allowing time for clearance of HPV infection 
before the follow-up test was undertaken. 
The age-standardised detection of high-grade abnormalities remained steady at 1.3 per 100 
cytology tests for all years from 2004 to 2007, and was slightly higher from 2008 to 2011 
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(Table 2.1). There are several possible reasons for this small increase, but it was not a key 
parameter determined for SMC monitoring, which focused on cervical cancer as the key 
outcome. Overall, the rate of all abnormalities combined decreased between 2004 and 2011. 
Table 2.1: Abnormalities detected by cytology in women aged 20–69, 2004 to 2011 
 2004 2005 2006 2007 2008 2009 2010 2011 
Low-grade abnormalities 
Number 109,814 114,257 103,841 97,916 92,013 83,933 78,510 84,540 
Crude rate 5.4 5.6 5.1 4.7 4.5 4.0 3.9 4.1 
AS rate 5.4 5.5 5.1 4.6 4.5 4.0 3.9 4.1 
95% CI 5.3–5.4 5.4–5.5 5.0–5.1 4.6–4.6 4.4–4.5 4.0–4.0 3.9–3.9 4.1–4.2 
High-grade abnormalities 
Number 26,975 26,534 26,165 28,297 29,176 28,054 28,491 30,253 
Crude rate 1.3 1.3 1.3 1.4 1.4 1.3 1.4 1.5 
AS rate 1.3 1.3 1.3 1.3 1.4 1.3 1.4 1.5 
95% CI 1.3–1.3 1.2–1.3 1.2–1.3 1.3–1.3 1.4–1.4 1.3–1.3 1.4–1.4 1.4–1.5 
All abnormalities (low-grade, high-grade and cancer)   
Number 137,010 141,016 130,234 126,442 121,400 112,188 107,261 115,026 
Crude rate 6.8 6.9 6.4 6.0 5.9 5.4 5.3 5.6 
AS rate 6.7 6.7 6.3 5.9 5.9 5.4 5.3 5.6 
95% CI 6.6–6.7 6.7–6.8 6.3–6.4 5.9–6.0 5.8–5.9 5.3–5.4 5.3–5.4 5.6–5.6 
Notes 
1. Low-grade abnormalities are cytology test results S2, S3 and E2; high-grade abnormalities are cytology results S4, S5, S6, E3,  
E4 and E5. All abnormalities are cytology results S2, S3, S4, S5, S6, S7, E2, E3, E4, E5 and E6 (see Table 3.1). 
2. Crude rate is the number of low-grade, high-grade, or all abnormalities detected by cytology as a proportion of the total number  
of cytology tests; age-standardised (AS) rate is the number of low-grade, high-grade, or all abnormalities detected by cytology as a 
proportion of the total number of cytology tests age-standardised to the Australian population at 30 June 2001. 
3. Data in this table are based on the number of abnormalities detected, not the number of abnormal cytology tests—in a small proportion of 
cytology tests there may be more than one abnormality detected, both of which will be counted. 
Source: AIHW 2013.  
Cytologically detected abnormalities by age 
For abnormalities detected by cytology, Figure 2.1A shows the age distribution of low-grade 
abnormalities and Figure 2.1B the age distribution of high-grade abnormalities. 
Abnormalities are most common in younger women, which is attributed to HPV infections 
that occur frequently after sexual debut. Low-grade abnormalities are highest in women 
aged less than 20 and in those aged 20–24 (Figure 2.1A), while high-grade abnormalities are 
relatively low in women aged less than 20 and peak in women aged 20–29 (Figure 2.1B). 
Detection of both low-grade and high-grade abnormalities then decreases with increasing 
age, only increasing again in women aged 70 or over (Figures 2.1A and 2.1B). 
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A 
 
B 
 
Note: The number of low-grade or high-grade abnormalities detected by cytology are shown as a proportion of the total number of cytology tests 
for each 5-year age-group (crude rates only). 
Source: AIHW 2013. 
Figure 2.1: Low-grade (A) and high-grade (B) abnormalities detected by cytology, by age, 2011 
2.2 Cervical abnormalities detected by histology 
In 2011, there were 38,122 abnormalities (low-grade, high-grade or cancer) detected in the 
75,589 histology tests for women aged 20–69 (50.4 per 100 histology tests). Of these 
abnormalities, 14,566 (38.3%) were low-grade and 22,676 (59.6%) were high-grade, with 
cancer making up the remaining 2.1% (Table 2.2). 
Histologically detected abnormality trends 
Low-grade abnormalities detected by histology decreased from 20,239 in 2004 to  
14,566 in 2011 (Table 2.2). The overall decrease, across all age groups, is in line with expected 
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changes in detection of low-grade abnormalities resulting from changes to the recommended 
management of women with low-grade abnormalities as part of the current NHMRC 
guidelines introduced in 2006. The 2011 data suggest the trend may have stabilised following 
this change but further data are required in order to confirm this. 
Box 2.3: Histology explained 
Whereas cytology is performed for all women who participate in cervical screening (since 
each Pap test performed yields a cytology sample for analysis), histology is only performed 
on a small proportion of these women. This is because the majority of Pap tests do not 
detect an abnormality, and thus do not require diagnostic follow-up (unless there is a 
clinical indication to do so). Usually only high-grade or endocervical abnormalities will be 
followed by histology, but details of appropriate management are outlined in the current 
NHMRC guidelines for asymptomatic women. 
In contrast, the detection of high-grade abnormalities by histology increased from 19,681 in 
2004 to 22,676 in 2011 for women aged 20–69 (an increase from 21.2 to 25.9 per 100 histology 
tests, age-standardised) (Table 2.2). Again, there are several possible reasons for this increase, 
but it was not a key parameter determined for SMC monitoring which focused on cervical 
cancer as the key outcome. Overall, the rate of all histologically detected abnormalities 
combined remained comparatively steady between 2004 and 2011. 
Table 2.2: Abnormalities detected by histology in women aged 20–69, 2004 to 2011 
 2004 2005 2006 2007 2008 2009 2010 2011 
Low-grade abnormalities        
Number 20,239 19,576 18,003 16,602 15,347 14,576 14,018 14,566 
Crude rate 26.5 26.0 24.8 23.2 21.1 20.1 19.4 19.3 
AS rate 23.0 22.2 21.4 20.2 18.4 17.6 17.2 17.4 
95% CI 22.7–23.4 21.9–22.6 21.1–21.8 19.9–20.6 18.1–18.7 17.3–17.9 16.9–17.5 17.1–17.7 
High-grade abnormalities        
Number 19,681 20,200 20,063 21,067 22,102 22,031 22,104 22,676 
Crude rate 25.8 26.8 27.7 29.4 30.4 30.4 30.6 30.0 
AS rate 21.2 22.0 22.9 24.4 25.2 25.4 25.9 25.9 
95% CI 20.9–21.5 21.6–22.3 22.6–23.3 24.1–24.8 24.8–25.5 25.0–25.7 25.6–26.3 25.5–26.2 
All abnormalities (low-grade, high-grade and cancer)   
Number 40,653 40,603 38,825 38,476 38,325 37,380 36,940  38,122 
Crude rate 53.3 53.9 53.5 53.7 52.7 51.6 51.1 50.4 
AS rate 45.5 45.8 45.8 46.2 45.1 44.4 44.4 44.6 
95% CI 45.0–46.0 45.3–46.2 45.3–46.3 45.7–46.7 44.7–45.6 43.9–44.9 44.0–44.9 44.1–45.0 
Notes 
1. Low-grade abnormalities are histology test results HS02 and HE02; high-grade abnormalities are histology results HS03 and HE03. 
All abnormalities are histology test results HS02, HS03, HS04, HE02, HE03 and HE04 (see Table 4.1).  
2. Crude rate is the number of low-grade, high-grade, or all abnormalities detected by histology as a proportion of the total number of 
histology tests; age-standardised (AS) rate is the number of low-grade, high-grade, or all abnormalities detected by histology as a  
proportion of the total number of histology tests age-standardised to the Australian population at 30 June 2001. 
3. This is the number of abnormalities detected, not the number of abnormal histology tests—in a small proportion of histology tests there may 
be more than one abnormality detected, both of which will be counted. 
Source: AIHW 2013.  
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Histologically detected abnormalities by age 
For abnormalities detected by histology, Figure 2.2A shows the age distribution of low-grade 
abnormalities and Figure 2.2B the age distribution of high-grade abnormalities. 
Similar to abnormalities detected by cytology, abnormalities detected by histology were most 
common in younger women (HPV infections are common in the years following sexual 
debut). However, because low-grade cytology is not routinely followed up with histology 
under the current NHMRC guidelines (NHMRC 2005), low-grade histology was less 
frequently detected than high-grade histology, and is more reflective of biopsy rates than the 
true incidence of disease (Figure 2.2A). The age distribution of high-grade abnormalities 
showed a peak in women aged 20–34, thereafter declining sharply with increasing age 
(Figure 2.2B). 
A 
 
B 
 
Note: The number of low-grade or high-grade abnormalities detected by histology are shown as a proportion of the total number of histology tests 
for each 5-year age-group (crude rates only). 
Source: AIHW 2013. 
Figure 2.2: Low-grade (A) and high-grade (B) abnormalities detected by histology, by age, 2011 
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2.3 Women with high-grade abnormalities detected 
by histology (high-grade abnormality detection 
rate) 
High-grade abnormality detection rate in 2011 
The high-grade abnormality detection rate is defined as the number of women (not tests) 
with a high-grade abnormality detected by histology per 1,000 women screened. This differs 
from the previous section in which abnormalities were counted, and means that any given 
abnormality will only be counted once in a calendar year. Presenting the number of women 
with a high-grade abnormality as a proportion of the number of women screened also yields 
information that essentially removes the effect of changes in the number of women screened. 
High-grade abnormalities have a greater probability of progressing to invasive cancer than 
low-grade abnormalities (although it should be noted that high-grade abnormalities do not 
always progress, with one study suggesting that at least 80% of high-grade abnormalities 
regress spontaneously (Raffle et al. 2003). Detection of high-grade abnormalities provides an 
opportunity for treatment before cancer can develop, thus the NCSP aims to detect  
high-grade abnormalities in line with its broader aim to reduce the incidence of cervical 
cancer. 
In 2011, there were 16,635 women with a high-grade abnormality detected by histology 
(different to the number of high-grade abnormalities per 100 histology tests presented in Table 
2.2), which equates to a high-grade abnormality detection rate of 8.4 for women aged 20–69 
(Table 2.3). This means that, for every 1,000 women screened, 8.4 had a high-grade 
abnormality found, providing an opportunity for treatment before possible progression to 
cervical cancer. 
High-grade abnormality detection rate trends 
The high-grade detection rate increased from approximately 7.7 between 2004 and 2007 to 
8.4 per 1,000 women screened in 2011 (Table 2.3). Again, there are several possible reasons. 
Earlier AIHW data provide evidence of an increase occurring from around 2002 (AIHW 
2013). 
In contrast, there has been a steady decline in high-grade abnormality detection in women 
aged less than 20. Although this decline appeared to commence earlier, the decrease between 
2010 and 2011 from 7.8 to 7.1 for women aged less than 20, and the accompanying decrease 
from 19.7 to 17.4 for women aged 20–24 between 2010 and 2011 corresponds with the 
commencement of the HPV vaccination program. [Note: this commenced in 2007, with girls 
vaccinated during the catch-up program (2007‒2009) now becoming eligible for screening (a 
trend noted in Brotherton et al., 2011).] As the cohort of vaccinated girls becomes older, a 
decline in the high-grade abnormality detection rate in the 20–24 age group is already 
apparent in 2011 (Table 2.3; Figure 2.3).  
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Table 2.3: High-grade abnormality detection rate, by age, 2004 to 2011  
Age group 
(years) 2004 2005 2006 2007 2008 2009 
 
2010 
 
2011 
<20 14.5 13.2 13.2 11.6 10.8 8.9 7.8 7.1 
20–24 20.3 20.2 19.9 18.9 21.3 19.9 19.7 17.4 
25–29 17.7 17.7 17.7 17.8 19.3 19.0 19.9 19.4 
30–34 11.6 11.6 11.6 11.5 12.7 12.8 13.6 14.0 
35–39 7.1 7.0 7.2 7.3 7.8 7.6 8.3 9.0 
40–44 4.6 4.4 4.7 4.7 4.8 4.7 4.9 5.5 
45–49 3.1 3.1 3.2 3.2 3.3 3.3 3.5 3.8 
50–54 1.7 1.7 1.9 1.9 2.0 1.9 2.1 2.2 
55–59 1.5 1.6 1.5 1.4 1.3 1.3 1.7 1.7 
60–64 1.2 1.4 1.2 1.2 1.3 1.2 1.2 1.4 
65–69 1.0 1.0 1.4 1.3 1.3 1.1 1.1 1.1 
70+ 3.1 3.0 2.8 2.4 2.6 2.6 3.4 2.7 
Ages 20–69   
Crude rate 7.9 7.9 7.8 7.8 8.4 8.1 8.4 8.4 
AS rate 7.7 7.7 7.8 7.7 8.3 8.1 8.5 8.4 
95% CI 7.6–7.9 7.6–7.8 7.6–7.9 7.5–7.8 8.2–8.5 8.0–8.2 8.3–8.6 8.3–8.6 
Note: Crude rate is the number of women with a high-grade abnormality detected by histology per 1,000 women screened; age-standardised (AS) 
rate is the number of women with a high-grade abnormality detected by histology per 1,000 women screened, age-standardised to the Australian 
population at 30 June 2001. 
Source: AIHW 2013.  
 
 
 
Note: The number of women with a high-grade abnormality detected by histology are shown per 1,000 women screened for each 5-year age 
group (crude rates only). 
Source: AIHW 2013.  
Figure 2.3: High-grade abnormality detection rate, by age, 2006, 2010 and 2011 
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It is not entirely clear why there has been an increase in high-grade abnormality detection 
(which, as noted below, is primarily due to a modest increase in detection for women aged 
25–39), and there may be various contributing factors. Some of these may be related to a 
change in classification of abnormalities as a result of the change in guidelines (for instance if 
a pathologist is unsure whether an abnormality should be classified as low-grade or high-
grade, they may be more inclined to classify it as a high-grade under the new Guidelines 
because high grade abnormalities are monitored more conservatively). 
The SMC noted this increase in high-grade abnormalities, and gave due consideration to its 
implications. The view of the SMC is that, although it was not entirely clear why there had 
been an increase in high-grade abnormalities, the change in management guidelines could 
not be excluded as a cause. It was reassuring that this increase was not accompanied by an 
increase in cervical cancer incidence, which was the key outcome parameter for SMC 
monitoring. 
2.4 Cervical cancer incidence 
Incidence of cervical cancer in 2009 
In 2009, there were 771 new cases of cervical cancer in Australian women. This is equivalent 
to 7 new cases for every 100,000 women in the population. Of these 771 new cases, 631 were 
in women aged 20–69, the target population of the NCSP. 
In the broader context of cancers diagnosed in Australian women (and excluding basal cell 
and squamous cell carcinoma of the skin), cervical cancer was the 12th most commonly 
diagnosed cancer in Australian women in 2009, and comprised 1.5% of all cancers diagnosed 
in women (AIHW & AACR 2012). The mean age at diagnosis of cervical cancer was 50.2 
years, and the risk of diagnosis with cervical cancer was 1 in 198 by age 75 years and 1 in 162 
by age 85 (AIHW & AACR 2012). 
Incidence of cervical cancer trends 
While incidence had been slowly decreasing before the organised national screening 
program, the decrease accelerated after the establishment of the program. Since then the 
incidence has almost halved between 1991 and 2009 from 17.2 to 9.0 new cases per 100,000 
women (a decrease in the number of new cases from 895 to 631) for women aged 20–69 
(Figure 2.4).  
Since an historic low in 2002, rates have remained relatively stable at 9 new cases per  
100,000 women (Figure 2.4).  
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Note: Rates shown are the number of new cases of cervical cancer per 100,000 women, age-standardised to the Australian  
population at 30 June 2001. 
Source: AIHW 2013. 
Figure 2.4: Incidence of cervical cancer in women aged 20–69, by year, 1982 to 2009 
Incidence of cervical cancer trends beyond 2009 
The Victorian, Queensland, Western Australian, South Australian and Tasmanian cancer 
registries were able to assist by providing the SMC with cervical cancer incidence data for 
2010 and 2011. The AIHW analysed these data for the SMC. 
Incidence rates for 2010 and 2011 in these five states did not vary outside the range observed 
in the previous 5 years. The data indicated that the stable rate for the country as a whole in 
2002–2009 was continuing, at least in these five states. 
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Incidence of cervical cancer by age 
 
Note: The number of new cases of cervical cancer per 100,000 women are shown for each 5-year age group (crude rates only). 
Source: AIHW 2013. 
Figure 2.5: Incidence of cervical cancer in women, by age, 1985–1989, 1995–1999 and 2005–2009 
Historical age-specific trends reveal the effect of the cervical screening program on incidence. 
Calculated over 5-year periods to increase stability and comparability of rates, age-specific 
incidence is shown for 1985–1989, 1995–1999 and 2005–2009 in Figure 2.5.  
It is evident that incidence decreased across all age groups from 1985–1989 to 2005–2009. 
Further, in 1985–1989, before the NCSP was introduced, there was a clear second (and 
higher) peak in incidence in women aged 60 onwards, which has since fallen (Figure 2.5). 
Incidence by histological type 
Table 2.4: Incidence of cervical cancer in women aged 20–69, by histological type, 2008 
Type of cervical cancer 
New 
cases AS rate 
% of cervical 
cancers 
(% of 
carcinomas) 
1: Carcinoma 630 9.2 98.3 (100.0) 
1.1: Squamous cell carcinoma 419 6.1 65.4 (66.5) 
1.2: Adenocarcinoma 164 2.4 25.6 (26.0) 
1.3: Adenosquamous carcinoma 21 0.3 3.3 (3.3) 
1.4: Other specified and unspecified carcinoma 26 0.4 4.1 (4.1) 
2: Sarcoma 3 0.0 0.5 . . 
3: Other specified and unspecified malignant neoplasm 8 0.1 1.2 . . 
Total 641 9.4 100.0 . . 
Note: Age-standardised (AS) rate is the number of new cases per 100,000 women, age-standardised to the Australian population 
at 30 June 2001; rates based on less than 20 new cases should be interpreted with caution. Per cents shown are crude only. 
Source: AIHW Australian Cancer Database. 
In 2008, of the 641 cervical cancers diagnosed in women aged 20–69, 630 (98.3%) were 
carcinomas, 3 (0.5%) were sarcomas, and 8 (1.2%) were classified as other and unspecified 
malignant neoplasms (Table 2.4). Of the 630 carcinomas diagnosed, squamous cell carcinoma 
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comprised the greatest proportion at 66.5%, followed by adenocarcinoma at 26.0%, and 
adenosquamous carcinoma at 3.3% in women aged 20–69 (Table 2.4). 
Trends in age-standardised incidence rates for women aged 20–69 between 1982 and 2008 for 
squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma and other 
carcinomas are shown in Figure 2.6. 
 
Note: The number of new cases of squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, and other carcinoma of the cervix, 
are shown per 100,000 women, age-standardised to the Australian population at 30 June 2001. 
Source: AIHW Australian Cancer Database. 
Figure 2.6: Incidence of carcinoma of the cervix (squamous cell carcinoma, adenocarcinoma, 
adenosquamous carcinoma and other carcinoma) in women aged 20–69, by year, 1982 to 2008 
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3 Outcomes of projects to assess the 
safety of the guidelines  
3.1 Are women with a pre-invasive cervical 
abnormality more likely to be diagnosed with a 
subsequent cervical cancer since the 
introduction of the guidelines? 
The primary analyses that the SMC considered involved comparing the occurrence of 
cervical cancer after an abnormality following the guideline change with the occurrence 
beforehand. Specifically, occurrences of cervical cancer following a low-grade squamous 
abnormality detected by cytology, or a high-grade abnormality detected by histology, were 
compared across these periods since they were relevant to the two major changes to the 
guidelines. 
Reassuringly, there was no overall increase in cervical cancers found following detection of 
these abnormalities in women managed under the new NHMRC Guidelines compared with 
that which applied under the previous NHMRC Guidelines. 
Detailed findings are presented for cervical cancer after a low-grade squamous abnormality 
detected by cytology, since this analysis includes an adequate number of cancers and time 
elapsed per person for meaningful conclusions.  
No overall increase in cervical cancer was found after detection of pre-invasive 
abnormalities in women managed under the new NHMRC Guidelines when compared 
with numbers of cervical cancers after pre-invasive abnormalities in women managed 
under the previous NHMRC Guidelines. 
While brief results are presented for an interim analysis that looks at cervical cancer after a 
high-grade abnormality detected by histology, and early findings of women who have 
completed test of cure are also given, neither of these analyses had adequate data to provide 
definitive results. 
Methodology 
The following methodology, endorsed by the SMC, compares the incidence of cervical cancer 
after a Pap test result of possible or definite low-grade squamous intraepithelial lesion, or a 
high-grade histology result, in women managed under the 1994 guidelines compared to 
those managed under the 2005 guidelines. 
The AIHW undertook these analyses for the SMC. 
Aim: To compare the incidence of cervical cancer after a low-grade squamous cytology 
result before and after the introduction of the 2005 NHMRC Guidelines.  
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Data source and parameters 
All data were supplied by the state and territory cervical cytology registers, with the 
exception of South Australia, which is excluded from the analyses in this report due to data 
not being available at this time. The Chief Health Officer in each state and territory and the 
AIHW Ethics Committee approved the supply and use of these data. 
Data for women managed under the 1994 guidelines (referred to as ‘baseline’) were collected 
from 1 January 1999 to 30 June 2006, with data analysed from 1 January 2001 to 30 June 2006. 
Data for women managed under the 2005 guidelines (referred to as ‘ongoing’) were collected 
from 1 July 2006, with data analysed from 1 January 2007 to 30 June 2012, allowing a 6-
month ‘wash out’ period after the introduction of the 2005 guidelines (as inclusion of this 
period could potentially include women with mixed investigation and management).  
Only women aged 20–69 (the target age group of the NCSP) are included in analyses. 
Cohort design 
Women enter the cohort with a Pap test result of possible or definite low-grade squamous 
intraepithelial lesion in either the baseline or ongoing time periods. Their progress is 
measured until they are either diagnosed with cervical cancer or leave the cohort either at the 
end of follow-up (2 or 5 years) or through censoring at the end of the observation period (see 
Box 3) or due to death. Women who have previously had histologically confirmed high-
grade disease or a diagnosis of cervical cancer are excluded from entering the cohort. 
Box 3.1: Statistical terminology 
In a cohort design, there is usually an end-point to the study, on which date all people who 
are still in the cohort (that is, have not been censored (stopped) for another reason prior to 
this date) are censored due to ‘end of observation period’. In these data, the end-point of 
the baseline data is the 30 June 2006 (just prior to the introduction of the new guidelines), 
and the end-point of the ongoing data is 30 June 2012 (to reflect the end-point of the data 
supplied). 
This study also uses a defined follow-up period, by which women are censored after 2 
years if they have not previously been censored for another reason.  
Person-time, in years, is calculated by measuring the time from each woman's entry into the 
cohort until they are either diagnosed with cancer or leave the cohort (at the end of follow-
up or through censoring at the end of the observation period or due to death). 
Table 3.1 describes the selection of women for inclusion in the baseline and ongoing cohorts. 
Table 3.1: Number of low-grade squamous cytology tests, women aged 20–69, baseline and ongoing 
cohorts  
Note: Baseline is 1 January 2001 to 30 June 2006; ongoing is 1 January 2007 to 30 June 2012. 
Source: AIHW analysis of state and territory cervical cytology register data.  
 Baseline Ongoing 
Low-grade squamous cytology in women aged 20‒69 541,711 442,846 
Exclusion of women with previous histologically confirmed high-grade disease 512,685 411,286 
Exclusion of women with previous cervical cancer diagnosis 512,413 411,073 
Removal of duplicate cytology tests (number of women in cohort) 512,315 411,041 
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Statistical analyses 
Proportional hazards regression was used to estimate the hazard ratio (with 95% confidence 
intervals (CI)) for an increase or decrease in cancer incidence in the ongoing cohort relative to 
the baseline cohort (see Appendix D). 
A Z-score (a function of the proportional hazards estimate and its standard error) for each  
6-month monitoring point was placed into the context of safety monitoring boundaries set by 
the methodology, whereby a warning flag is raised if the hazard ratio increased and this 
exceeds the 10% α-level, and an immediate action required flag is raised if this exceeds the 
5% α-level. Due to the sequential nature of the monitoring process, adjustment was made for 
multiple testing (Wang & Tsiatis 1987). 
Cumulative incidence curves, were calculated for baseline and ongoing incidence over the 2-
year follow-up period (more information is provided in Appendix D). 
Results 
The proportional hazard ratio calculated between the baseline and ongoing cohorts, with 2 
years follow-up, was 0.94 (95% CI 0.73–1.19). This is not statistically significantly different to 
1, indicating no statistically significant change in the risk of cancer after a low-grade 
squamous cytology under the new guidelines compared to the previous guidelines. 
There was no statistically significant change in the risk of cancer after a low-grade 
squamous cytology under the new NHMRC Guidelines compared to the previous 
guidelines. 
The proportional hazard ratio was also calculated with 5 years follow-up. These data are 
shown in Table 3.2, below.  
Table 3.2: Summary of low-grade cohort data, baseline and ongoing, 2 and 5 years follow-up 
 Baseline Ongoing Hazard ratio 
2 years follow-up    
Low-grade abnormalities 512,315 411,041 0.94 
Total person-time in cohort (years) 680,683 579,058 (0.74–1.19) 
Cancers in cohort 158 119  
5 years follow-up    
Low-grade abnormalities 512,315 411,041 1.03 
Total person-time in cohort (years) 1,042,976 918,151 (0.83–1.27) 
Cancers in cohort 188 159  
Note: Baseline is 1 January 2001 to 30 June 2006; ongoing is 1 January 2007 to 30 June 2012. 
Source: AIHW analysis of state and territory cervical cytology register data.  
The proportional hazards model was adjusted for the potential confounders of year and age 
(with age centred around age 50), but this did not have a significant effect on model results. 
Monitoring checkpoints and their respective critical values are shown in Table 3.3, as are the 
hazard ratio, Z-score and action for each of the eight monitoring checkpoints completed. As 
shown in Figure 3.1, the adjusted hazard ratio estimates for low-grade cytology for all of the 
monitoring checkpoints are well within the critical values set for these respective 
checkpoints. 
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Table 3.3: Critical values calculated for monitoring checkpoints 
Monitoring 
checkpoint 
Observation 
period ending  
Hazard 
ratio 
Z-score  
(test statistic) 
Critical values for 
warning flag 
(exceeds 10%  
α-level) 
Critical values for 
immediate action 
flag (exceeds 5%  
α-level) 
Action 
1 December 2008  1.24 0.61 3.20 3.67 Continue 
2 June 2009  1.08 0.49 2.69 3.08 Continue 
3 December 2009 1.01 0.07 2.43 2.79 Continue 
4 June 2010  1.08 0.57 2.26 2.59 Continue 
5 December 2010 1.06 0.45 2.14 2.45 Continue 
6 June 2011  0.99 ‒0.08 2.05 2.34 Continue 
7 December 2011 0.95 ‒0.41 1.97 2.25 Continue 
8 June 2012  0.94 ‒0.51 1.90 2.18 None required 
Note: Critical values for monitoring test checkpoints were calculated based on Wang & Tsiatis (1987). 
Source: AIHW analysis of state and territory cervical cytology register data. 
 
The SMC was required to raise a warning flag if the incidence was increased and the test 
score exceeded the 10% α-level, and to raise an immediate action required flag if this 
score exceeded the 5% α-level.  
The safety monitoring boundaries are illustrated in Figure 3.1. 
 
Figure 3.1 Boundaries for adjusted hazard ratio 
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The critical values are described in the tables and illustrated in the figures. The funnel shape 
of the boundary plot illustrates the critical values decreasing with each monitoring point (set 
at the end of each observation period). The horizontal axis represents each of the monitoring 
points and the vertical axis represents the test score and critical values at each checkpoint. 
The test statistic is denoted by a black circular symbol.  
The approach was that, if the test score exceeded the critical values generated from the 
sequential design, appropriate action would be taken, otherwise monitoring would continue. 
The SMC was required to raise a warning flag if the test score exceeded the 10% α-level, and 
to raise an immediate action required flag if this exceeded the 5% α-level.  
Cumulative incidence curves are based on the Kaplan-Meier product limit method of time to 
event estimation. Kaplan-Meier methods are standard methods used to estimate the 
frequency distribution (or incidence curve) of an event over time (see Appendix D). In this 
case it was the time, measured in weeks, to a cervical cancer diagnosis following the 
identification of either a low-grade cytology abnormality or a high-grade histology 
abnormality.  
Figure 3.2 shows the Kaplan-Meier cumulative cervical cancer incidence curves over 2 years 
(104 weeks) of follow-up for baseline and ongoing cohorts. This shows the time, measured in 
weeks, to a cervical cancer diagnosis following a low-grade cytology abnormality. Again, no 
increase in incidence of cervical cancer was observed following the introduction of the new 
guidelines. 
 
 
Source: AIHW analysis of state and territory cervical cytology register data. 
Figure 3.2: Cumulative rate of cervical cancer by time in cohort, baseline and ongoing 
Additional results for high-grade abnormalities 
In addition to the previously described analyses of incidence of cervical cancer after a low-
grade squamous cytology, two additional analyses were undertaken to look at incidence of 
cervical cancer after a histologically confirmed high-grade abnormality. 
Under the previous guidelines, women treated for a histologically confirmed high-grade 
abnormality were advised to continue with annual Pap tests ad infinitum. Under the new 
guidelines, women treated for a histologically confirmed high-grade abnormality are eligible 
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to undergo a ‘test of cure’. A test of cure involves a cytology test and an HPV DNA test 
around 12 months after the completion of treatment, followed by another cytology test 
together with another HPV DNA test 12 months later. If both sets of cytology and HPV DNA 
tests are negative, then a woman is deemed to have completed her test of cure, and can 
return to regular 2-yearly cervical screening. This is the screening interval currently 
recommended for women who have no symptoms or history suggestive of cervical 
pathology. 
The first analysis was an interim measure looking at cervical cancer incidence in the 2 years 
following a histology result of high-grade abnormality. As there are no management changes 
between the previous guidelines and the new guidelines for this period, this analysis does 
not address the safety of new management practices. This interim assessment was 
undertaken in the interests of monitoring the whole screening pathway and in advance of 
sufficient data arising to allow assessment of cervical cancer incidence after a completed ‘test 
of cure’ and return to routine 2-yearly screening.  
A comparison of cervical cancers that occurred in the 2 years following a 12-month clinical 
management period immediately following a histologically confirmed high-grade 
abnormality was made. The numbers were small with 22 cancers found for the baseline 
period and 36 following introduction of the new guidelines. Proportional hazards regression 
did not reveal this to be a statistically significant increase and the 10% α-level was not 
reached to raise an alert. 
A comparison of the cervical cancers that occurred following a histologically confirmed 
high-grade abnormality between the two guidelines did not raise a warning flag at the 
10% α-level. 
It should be reiterated that in the period of time so far studied after high-grade abnormalities 
were detected by histology for this interim measure, there had been no change in the 
management. Accordingly, even if a statistically significant increase had been found, it 
would not have related to a change in NHMRC Guidelines. It is planned that, as a further 
check, numbers of cervical cancers occurring after high-grade histology will continue to be 
monitored to gain more definitive results. 
The second analysis assessed cervical cancer incidence after women had completed ‘test of 
cure’. Under the new guidelines, unless both sets of cytology and HPV DNA tests are 
negative, a woman has not completed her test of cure, and is recommended that she has a 
cytology test and an HPV DNA test every 12 months until she achieves two consecutive 
negative cytology and HPV DNA tests 12 months apart. Completing the ‘test of cure’ 
represents a change from the previous guidelines that recommended annual cervical 
screening ad infinitum following treatment of a high-grade histological abnormality. 
Due to the time required after high-grade diagnosis to complete treatment, undergo and 
eventually complete test of cure, and be returned to routine 2-yearly screening, there are at 
present only limited data available on cancer outcomes for these women. The present data 
include women aged 20–69 with no prior history of cervical cancer with histologically 
confirmed CIN II or CIN III diagnosed since 1 January 2007, with consecutive negative 
cytology and HPV DNA test results at least 10 months apart (10 months was used instead of 
12 months to allow for women who were tested earlier). 
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Using this methodology, only 4,360 women were identified who had completed test of cure 
with the limited amount of follow-up data available. Importantly, there were no cervical 
cancers diagnosed in any of these 4,360 women who had completed their test of cure. 
There were no cervical cancers diagnosed in any of the 4,360 women who had completed 
their ‘test of cure’. 
Cervical cancer incidence after completion of test of cure will continue to be monitored, and 
should provide more definitive findings as more follow-up data become available. 
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3.3 What did the review of cervical cancer cases 
included in the analyses reveal? 
A review of the screening histories of women diagnosed with cancer was recognised as a key 
component of safety monitoring for the new guidelines. A cancer audit is an important tool 
to monitor program effectiveness and identify areas where improvements to the program 
can be made. A number of countries have commenced comprehensive audits of their cervical 
screening programs, in particular New Zealand and the United Kingdom.  
Aim: To conduct a qualitative review of cancers arising in the study cohorts. 
The primary goal of this audit was to conduct a qualitative review of cancers arising in the 
study cohorts, providing an additional perspective to the statistical analysis being conducted 
as part of the safety monitoring of the NHMRC Guidelines. The scope of this audit is limited 
to a qualitative review of de-identified data that the AIHW had received from the cervical 
cytology registers for the purpose of safety monitoring. Specifically it was outside the scope 
of this audit to review medical records or histology slides or seek information from treating 
medical practitioners.  
Methodology 
Relevant data on screening histories were supplied to the AIHW from cervical cytology 
registers for women with an index Pap test result with a low-grade squamous abnormality 
who had a cancer diagnosed within 5 years of the low-grade cytology result. Both censored 
cancers and cancer ‘events’ in the main analysis were reviewed as part of this audit. 
Data from women in periods of observation both before and after the introduction of the 
new guidelines were reviewed as there were no major differences in coding that would affect 
the interpretation of the data. 
The audit relates to the cohort of women included in the monitoring of the NHMRC 
Guidelines described above. It should be noted that this audit is not representative of the 
majority of cervical cancers that occur in Australian women who have a poor screening 
history or who have never been screened.  
To assist in interpretation, the cancer cases have been classified into broad categories based 
on how closely NHMRC management guidelines had been followed, based on the data 
available. This process was dependent on the available screening histories and no definitive 
classification can be made in the absence of colposcopy and treatment data. 
A small group within the SMC undertook these analyses specifically for the SMC. The group 
included representatives from the AIHW, the Victorian Cervical Cytology Registry, and the 
Australian Society of Colposcopy and Cervical Pathology. The state and territory cervical 
cytology registers supplied all data. The Chief Health Officer in each state and territory and 
the AIHW Ethics Committee approved the supply and use of these data. 
Limitations of data 
There are a number of important limitations to consider when interpreting the findings of 
this audit. The available data held by cervical cytology registers were largely limited to the 
cytology, histology and HPV testing for each woman diagnosed with cancer, supplemented 
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by the laboratory recommendation codes where they were recorded. Cervical cytology 
registers do not systematically collect data on treatment or colposcopy and symptom status 
is not recorded in a nationally consistent manner. 
Colposcopy data  
The cervical cytology registers operate under the relevant legislation for their state or 
territory, and receive data on cervical cytology and relevant cervical histology directly from 
reporting laboratories in a timely manner. However, cervical cytology registers do not 
receive systematic information on colposcopies performed.  
The lack of data on colposcopy precludes an accurate assessment of whether the guidelines 
were followed, as in most instances a colposcopy was recommended.  
Treatment data  
The cervical cytology registers do not systematically record information on the treatment of 
women involved in the screening program. Although information can sometimes be derived 
from details of the procedure recorded in the histopathology report, it is not always possible 
to tell what type of treatment was performed, or if a woman was treated at all. In the case of 
ablative treatment, there may be no associated report if no biological sample was taken.  
Symptom status 
Symptom status is able to be recorded, which allows women with symptoms who are 
identified as such at the time of their cervical cytology test to also be identified on the 
cervical cytology registers. However, the completeness of this field depends on both the 
clinicians requesting the Pap test and laboratories coding the information appropriately. The 
proportion of women with symptoms recorded was found to vary too much across states 
and territories to be regarded as reflecting any genuine differences in women with 
symptoms. The inconsistent use of the symptom code nationally led to this finding. 
Findings of the audit 
Low-grade cohort 
The screening histories were reviewed in women who developed a cancer following a  
low-grade cytology result.  
Broadly speaking, the cancer review found evidence that the guidelines had been followed in 
around half of the cervical cytology cases, as there was a record of a subsequent cytological 
or histological test being performed within the recommended interval.  
In the remainder of cases, it was not possible to determine whether the guidelines had been 
followed as information on colposcopy was unavailable if a biopsy had not been performed. 
Also, it was not possible to determine occasions when a woman had an early referral due to 
the presence of symptoms, due to the poor quality of recording of this information. 
Interestingly, 69% of cases had not had a negative screening history in the 3 years prior to the 
index low-grade cytology which entered them into the cohort. This proportion was even 
higher in women with no prior negative screening history that were diagnosed with cervical 
cancer within 6 months of the low-grade cytology. 
The rate of cancer following a low-grade abnormality in the ongoing cohort was 1 in 1,924 
women compared with the baseline cohort rate of 1 in 2,245 women. The review of cervical 
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cytology registers’ data on cancers after low-grade cytology for the ongoing cohort reflected 
a range of possible reasons for subsequent diagnosis including: 
• failure to diagnose the cancer in a timely manner (failure of colposcopy or biopsy) 
• inadequate prior screening history 
• possible underdiagnosis on cytology 
• in some cases, rapid progression of cancer.  
Based on the information available, it was not possible to distinguish between these 
possibilities in many instances and the reasons for diagnosis are likely to be multifactorial. 
The cancer case review was also conducted on cancers following women with a 
histologically confirmed high-grade abnormality, for which detailed results have not been 
shown in Chapter 3.1. Briefly, it was concluded that very few women had any significant loss 
to follow-up after a high-grade abnormality, suggesting the registry safety net in Australia is 
working well. However, as expected, most women had an inadequate screening history prior 
to cancer diagnosis which may have led to larger lesions that were more difficult to treat. 
None of the women examined appeared to have completed ‘test of cure’ at the time the 
review was conducted. 
Discussion 
Cancer audits are a useful tool for monitoring the quality of a screening program and 
identifying areas where improvements can be made. The focus of this review was on cancers 
arising after a screen-detected abnormality which represented only a proportion of cervical 
cancers diagnosed in Australia, since the majority of these cancers occur in unscreened or 
underscreened women.  
Overall, the cancer audit provides descriptive data to support the quantitative analysis being 
undertaken; however, it is limited because cervical cytology registers do not systematically 
collect data on colposcopy and treatment. Symptom status was also not recorded in the vast 
majority of cases in the study cohort. Given the data available for the review, the SMC 
concluded that a range of factors may have contributed to the cancers arising, following on 
from the detection of cytological abnormalities.   
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3.4 What did the survey of pathology laboratories 
reporting cervical cytology show? 
Pathology laboratories have a central role in the National Cervical Screening Program. More 
than 2 million cytology tests are collected and reviewed in Australian pathology laboratories 
each year. High-quality cervical cytology is a key component of the assessment and 
treatment of women with abnormalities that are a precursor to cervical cancer.  
Aim: To seek feedback from laboratories on the processes used to make 
recommendations for women with screen-detected cervical abnormalities. 
As part of a wider range of activities that the Safety Monitoring Committee (SMC) 
undertook, the committee sought feedback from laboratories on the processes used to make 
recommendations for women with screen-detected cervical abnormalities. With the 
assistance of the Royal College of Pathologists of Australasia (RCPA) Cytopathology Quality 
Assurance Program. A survey to assess reporting systems of pathology laboratories was 
distributed to 51 pathology laboratories that report cervical cytology. The responses from 
laboratories that returned the survey to the Department of Health are included in the 
analysis below.  
The survey received a response from 32 cytological laboratories, a participation rate of 
around 63%. New South Wales had the highest number of respondents (11 laboratories) 
followed by Western Australia and Victoria. There were no respondents from South 
Australia or the Northern Territory. Three-quarters of the laboratory services were found to 
report to only one cervical cytology register. A number of the larger laboratories (by number 
of staff), reported to more than one register, suggesting that there may be a correlation 
between the size of the service and the number of registers to which services report. 
However, there were exceptions to this pattern. 
A small group within the SMC undertook these analyses specifically for the Committee, 
including representatives from the Royal College of Pathologists of Australiasia and the 
National Cervical Screening Program Managers. 
Reporting cervical cytology results 
As described in Box 4 below, cytology laboratories often access information from cervical 
cytology registers on screening histories when making recommendations on patient 
management. The survey found the most common method of accessing patient screening 
histories from cervical cytology registers was through a batch enquiry—that is an electronic 
request for screening histories for a number of clients (accounting for just under half of the 
respondents), followed by online enquiry. Three laboratories reported that they did not have 
timely access to patient histories. 
A sizeable proportion (41%) of laboratories indicated that there are situations where no 
specific recommendation is made on a Pap test result. Additional comments indicated that, 
in cases dependent on clinical circumstances, recommendations were left to the clinician. 
That is, in patients with an abnormal smear and with a history of cervical abnormalities but 
no record on the registry or in patients referred to a gynaecologist or other specialist, 
recommendations were left to the clinician.  
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Box 4: Role of pathology laboratories in cervical screening 
Pathology laboratories play a major role in cervical screening. A Pap test involves a general 
practitioner, gynaecologist or reproductive health nurse collecting cells from the cervix and 
placing them on a glass slide. The slide is then sent to a pathology laboratory where the 
cells are examined by a cytologist or laboratory technician for abnormal cellular changes. 
These results are compared with the recorded screening history that the cervical cytology 
registers provide. Findings are reported back to the clinician along with a recommendation 
for patient management—the patient may be referred for further tests with a specialist to 
see if treatment is required. The cytology laboratories also notify the cervical cytology 
registers, allowing a record of the screening history to be established and maintained.  
High-quality cervical cytology in Australian pathology laboratories has been a key 
component of the cervical screening program, facilitated through the development of 
National Pathology Accreditation Advisory Council (NPAAC) Performance measures for 
Australian laboratories reporting cervical cytology (NPAAC 2006a). 
To understand how laboratories have integrated recommendations made in the NHMRC 
Guidelines in the preparation of cervical cytology reports, the laboratory services were asked 
whether they used an automated system using an algorithm based on the 2005 NHMRC 
Guidelines in making recommendations for cervical cytology reports.  
Manual systems outnumbered automated decision support systems with a majority of 
responding laboratories (62.5%) indicating that they were not using automated systems. The 
survey found that manual methods for entering results are still common, especially in the 
laboratories with a small number of employees. 
Reporting of symptom status 
Women who have symptoms that could indicate the presence of cervical cancer (such as 
abnormal bleeding) at the time of their cytology test are advised to be referred for further 
investigation and diagnostic testing, as the guidelines only cover asymptomatic women.  
In the National Cervical Cytology Coding Sheet introduced in July 2006, recommendation 
codes included the code RS Symptomatic-Clinical management required which allows women 
with symptoms who are identified as such at the time of their cervical cytology test to be 
identified on the cervical cytology registers. Symptom status provides useful additional 
clinical information for women on the register, and can alter the management recommended 
for these women.  
The majority of laboratories (81.3%) indicated that they had strategies in place for reporting 
Pap tests in patients with symptoms reported on the request form. Some of these strategies 
included modifying the standard comments or referral to a specialist. There was broad 
agreement on the types of symptoms that would lead to the laboratory to recommending 
Symptomatic-Clinical management on a Pap test result. When grouped together these 
symptoms tended to fall into three broad groups, most commonly ‘Abnormal or irregular 
bleeding’ (which included post-coital bleeding or post-menopausal bleeding), ‘Suspicious or 
abnormal Cervix’ and ‘Abnormal smear/other types of Clinical information’. 
Although there appeared to be broad agreement between laboratories in the manner of 
describing symptom status across states and territories, use of the RS code was found to vary 
between 0.02% and 2.38% in 2008–2009 (AIHW 2011). This variation was considered to be too 
large to be attributable to differences in women’s symptom status and was attributed to 
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inconsistent use of the symptom code nationally. It is not clear at what stage of the process 
this inconsistency lies and further investigation is required to increase the completeness of 
the symptom field. 
Cytology labour force 
The laboratories were questioned about the number and make-up of scientific staff within 
the laboratory (see Box 5). Qualified scientists outnumbered pathologists in nearly all of the 
laboratories, averaging 8.7 full-time equivalent (FTE) scientists compared with 3.5 FTE 
pathologists. There were low numbers of current trainees among the responding laboratories 
with an average of 0.5 FTE across all laboratories. 
While just over two-thirds (68.8%) of laboratories participating in the survey expressed a 
willingness to train new scientific staff, indicating that they currently train or have 
previously trained new staff, just over three in ten (31%) currently had a trainee. This rate 
was slightly higher (40%) in laboratories with more than ten employees. Common reasons 
for not conducting training included a lack of graduates with specific cytology qualifications 
to do the training; a view that there was no need to train new recruits due to a stable 
workforce; or the limited size and resources of the laboratory being regarded as insufficient 
to commit to training.  
The preference of most of the surveyed laboratories to recruit scientists or pathologists with 
formal qualifications in cytology is likely to improve the quality of the program. 
Box 5: Pathology laboratory staff 
Pathology laboratory staff include pathologists, scientists and cytotechnologists. 
A pathologist involved in gynaecological cytology is required to be a Fellow of the Royal 
College of Pathologists of Australasia (RCPA) or hold an equivalent qualification. 
Screening staff must include scientists or cytotechnologists who hold qualifications which 
designate competence in cytology (scientists are required to have a relevant degree in 
science or applied science together with a minimum of 2 years full-time training/experience 
in a National Association of Testing Authorities/RCPA-accredited laboratory for 
gynaecological cytology, and a senior cytotechnologist is required to have the equivalent of 
5 years full-time experience in cytology and to hold a qualification which designates 
competence in cytology) (NPAAC 2006b). 
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3.5 What did the compliance study reveal? 
There were several changes to the NHMRC Guidelines that affected the formulation of 
laboratory recommendations for reporting cervical cytology. The aim of the analysis shown 
in this chapter was to assess the compliance of laboratory recommendation codes with the 
NHMRC Guidelines in Victoria. Data were examined with the objective of: 
• describing the prevalence of laboratory recommendation codes for cervical cytology in 
Victoria, by year and by reporting laboratory 
• comparing laboratory recommendations with the guidelines’ recommendation for 
women who have had low-grade squamous intraepithelial abnormalities on cytology 
• comparing laboratory recommendation and the guidelines’ recommendation with actual 
screening interval to determine what proportion of women follow this recommendation. 
Aim: To assess the level of compliance of laboratory recommendation codes with the 
NHMRC Guidelines. 
Since the introduction of the Australian standard cervical cytology coding schedule in 2006, 
all Pap test registers have been collecting information on the laboratory recommendations 
accompanying Pap test reports.  
Table 3.4: Coding for management recommendations on laboratory reports 
Recommendation code Definition 
R0 No recommendation 
R1 Repeat smear 3 years 
R2 Repeat smear 2 years 
R3  Repeat smear 12 months 
R4 Repeat smear 6 months 
R5 Repeat smear 6-12 weeks 
R6  Colposcopy/biopsy recommended 
R7 Already under gynae management 
R8 Referral to specialist 
R9 Other management recommended 
RS Symptomatic—clinical management required 
Source: National Cervical Cytology Coding Sheet 2006. 
In Victoria, about 50% of all Pap tests are conducted at Victorian Cytology Service (VCS) 
Pathology, which has a decision support tool to assist scientists and pathologists to make 
recommendations compliant with the NHMRC Guidelines, taking account of the all relevant 
variables. Therefore it was important to compare recommendations made by VCS Pathology 
with those of other Victorian laboratories which may not use such a decision support tool for 
reporting cervical cytology. 
Methodology 
The prevalence of the recommendation codes that laboratories used was analysed for all 
cytology results between 1 January 2007 and 31 December 2011. 
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Concordance of laboratory recommendations and of the observed screening interval with the 
NHMRC Guidelines was analysed for women who had a low-grade abnormality detected on 
cytology in the period 1 July 2006 to 31 December 2011. Screening records (back to 1 January 
1997) were also retrieved for each of these women, in order to determine the appropriate 
follow-up management. The 2005 NHMRC Guidelines were used to determine the relevant 
recommendation codes based on each woman’s screening history, age at the time of the 
cytology test (<30, >=30), and the cytological result category (negative, low-grade squamous 
abnormalities and high-grade squamous abnormalities).  
The actual screening interval was also measured by examining the proportion of women 
who attended the next test within the interval recommended in the guidelines, as well as 
those who attended up to 3 months later than the interval recommended by the guidelines. 
Cumulative incidence figures of screening attendance, stratified by reporting laboratory, 
were reported. 
The University of New South Wales, on behalf of the VCS, performed analyses for the SMC 
using Victorian Cervical Cytology Register data. 
Results 
Changes observed in the recommendations made by pathology laboratories for low-grade 
abnormality test results were consistent with changes to the guidelines recommending a  
12-month repeat Pap test unless there is an exception to low-grade management. There had 
been some variation in the recommendation codes used for possible low-grade test results 
prior to the implementation of the guidelines which appears to have stabilised since the 
introduction of the new guidelines. 
In general, the concordance of laboratory recommendation codes with guideline 
recommendations was high for negative smears and for those where the result was a  
high-grade abnormality or the more serious diagnosis of cervical cancer. Concordance with 
guideline recommendations was high at all laboratories for low-grade abnormality results 
where standard management is recommended; that is women with a first low-grade 
abnormality result who did not fall into the ‘exceptions’ category. In these cases women are 
recommended to return at 12 months, and concordance was high in this group (96% for 
women aged less than 30; 89% for women aged 30 or more).  
For women in the low-grade abnormality management exception category (women aged 30 
years or more without a negative smear in the last 3 years), the guidelines give the option of 
either a repeat cytology in 6 months or immediate referral for colposcopy. Overall 
compliance with the low-grade management exceptions was 69%, however there was a very 
marked difference when stratified by laboratory (concordance with guidelines 99% at VCS 
Pathology; 27% at other Victorian laboratories overall). 
Generally, non-concordance with the guidelines appears to be due to recommending  
follow-up of a low-grade abnormality at 12 months when this was not consistent with the 
guidelines. In particular, this occurred for women with consecutive low-grade test results 
and for women aged over 30 without a recent negative history (in the latter case, this 
occurred only in Victorian laboratories other than VCS Pathology). 
Most women returned for their next test within 3 months of the interval that the guidelines 
recommended. Variations between the observed screening behaviour of women and the 
guidelines were generally explained by the relevant reporting laboratory’s recommendation, 
but not in all cases. Groups where attendance for any test within 3 months of the time 
 30 Report on monitoring activities of the National Cervical Screening Program Safety Monitoring Committee 
recommended for their follow-up was lowest were women who had two consecutive low-
grade abnormalities (63‒81%, depending on the time interval between the two consecutive 
low-grades), women aged less than 30 with an initial low grade result (79%), and women 
aged over 30 without a recent negative history (77%; though attendance in this last group 
differed markedly by reporting laboratory and so is likely related to the differing laboratory 
recommendations given). 
Women with an initial low-grade test result are recommended to attend two follow-up visits 
12 months apart. Compliance with the first round visit was reasonably high, although 
women aged less than 30 were less likely to attend than women over 30 (79% versus 90% 
within 15 months). This was not explained by differences in laboratory recommendations as 
a laboratory concordance was high for both groups (96% for <30; 89% for >=30). However, 
among these women who then had a negative Pap test result, compliance with their second 
round visit was much lower (66% within 15 months). This did not differ by reporting 
laboratory, nor was it explained by laboratory recommendations, as concordance of 
laboratory recommendations with the guidelines was high in this group (92%). 
Importantly, a high proportion (96%) of women with a cytology result of a possible  
high-grade abnormality or worse attended a follow-up visit within 6 months of this result, 
with little variation by reporting laboratory. 
Conclusion 
Trends in the use of recommendation codes for reporting cytology have changed since 2006 
in line with the new guidelines. Overall, use of recommendation codes examined in Victoria 
is broadly concordant with the guideline recommendations, with two important exceptions. 
The first relates to laboratory recommendations by Victorian laboratories other than VCS 
Pathology for women with low-grade abnormalities who are recommended for earlier 
management under the guidelines (‘exceptions’), but are continuing to receive 12-month 
repeat recommendations. Laboratories were not consistent in their compliance with this 
aspect of the guidelines. Given this was a controversial aspect of the guidelines and was 
designed to improve the safety of the new management pathway for women, further 
investigation of the reasons for this low compliance is recommended (although it is likely 
there was not decision support software). Similarly, there is lower concordance with the 
guidelines for women with a second consecutive low-grade abnormality test result, 
occurring at their first follow-up visit after an initial low-grade abnormality, particularly if 
women are late in attending their first visit. It would be valuable to determine if these figures 
are representative of practice in other states and territories and to consider how future 
compliance with the guidelines can be maximised.  
Overall, laboratory recommendation codes were broadly concordant with the changed 
management guidelines, although concordance was lower for low-grade management 
exceptions (that is, women aged over 30 and those who had a second low-grade 
abnormality). The use of automated decision support tools in laboratories that had them 
assisted them in complying with the new guidelines.  
Actual attendance by women for a follow-up test within 3 months of the recommended 
interval is generally high. An exception is women with a recent low-grade abnormality, 
whose first follow-up test was negative. Attendance is much lower than that observed after 
other recommendations to return in 12 months, and is not explained by laboratory 
recommendations which were generally consistent with the guidelines. It is possible that 
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women may interpret this recommendation differently after a negative test than they do after 
an abnormal test result.  
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4 Discussion 
The projects undertaken under the auspices of the National Cervical Screening SMC provide, 
in aggregate, a picture of the safety of the NHMRC Guidelines for the management of 
screen-detected abnormalities in asymptomatic women, introduced in Australia in July 2006. 
This picture of safety, while current in 2013, may require revision if new evidence comes to 
light in the future. Nonetheless, the overarching message is that, according to the methods 
currently used to assess the available evidence, the change in the guidelines has not led to an 
increase in cervical cancer in the 7 years since that change. 
Two main changes to the guidelines were the focus of analyses—women with low-grade 
squamous intraepithelial lesions, and women who undergo ‘test of cure’ following a treated 
high-grade abnormality. Both changes were for less conservative management than 
recommended in previous management guidelines. 
Evidence demonstrated that the change in management for women with a low-grade 
squamous intraepithelial lesion did not lead to an increase in cervical cancer, with a similar 
rate of cancers in women managed under the previous guidelines to that in women managed 
under the new guidelines. 
Evidence was only indicative for women undergoing test of cure since the change due to the 
time required for women to be treated for a high-grade abnormality and then complete test 
of cure. A maximum of 4,360 women had completed test of cure at the time of preparation of 
this report. Nonetheless it is relevant to note that women who completed the test of cure had 
a very low rate of subsequent high-grade abnormality, and to date, no woman who has 
completed test of cure was subsequently diagnosed with cervical cancer. Outcomes for 
women who have completed test of cure will continue to be monitored, and the summary 
findings published in the annual monitoring report for the National Cervical Screening 
Program, Cervical screening in Australia. 
To support the quantitative analyses, a qualitative analysis was also undertaken in the form 
of a cancer case review of the screening histories of women who were diagnosed with 
cervical cancer, having previously had diagnosis of only a low-grade squamous 
intraepithelial lesion. This exercise revealed that data from cervical cytology registers were 
insufficient to conduct a comprehensive case review, as registers do not systematically 
include colposcopy or treatment data. Symptom status was also not recorded in the vast 
majority of cases in the study cohort. Nonetheless, from the data available for the review, a 
range of factors are thought to have contributed to the cancers arising after the detection of 
cytological abnormalities. 
The laboratory survey gave insight into the process that the pathology laboratories who 
report on cervical cytology results have in place to support the new guidelines. 
The compliance study conducted on Victorian data was of great importance. This is because 
the analyses assessing differences in women managed under the previous versus the new 
guidelines are meaningless if the new guidelines are not adhered to, and women continue to 
be managed as per the previous guidelines.  
Overall, use of recommendation codes was found to be broadly concordant with the 
guideline recommendations, with two important exceptions. The first related to laboratory 
recommendations by Victorian laboratories other than VCS Pathology for women with  
low-grade abnormalities who were recommended for a repeat Pap test at 6 months or a 
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colposcopy under the guidelines, but were continuing to receive 12-month repeat 
recommendations. Given this was a controversial aspect of the guidelines and was designed 
to improve the safety of the new management pathway for women, further investigation of 
the reasons for this low compliance is recommended. Similarly, there was lower concordance 
with the guidelines for women with a second consecutive low-grade abnormality test result, 
occurring at their first follow-up visit after an initial low-grade abnormality, particularly 
where women were late in attending their first visit. It would be valuable to determine if 
these figures are representative of practice in other states and territories and to consider how 
future compliance with the guidelines can be maximised.  
Actual attendance by women for a follow-up test within 3 months of the recommended 
interval is generally high. There appears to be some difference by age in attendance for the 
first follow-up test, as women aged less than 30 were less likely to attend within 15 months 
of their initial low-grade abnormality than women over 30 (even after excluding the 
subgroup of women aged 30 or more who were recommended for earlier follow-up under 
the guidelines). This was not explained by differences in laboratory recommendations for the 
different age groups. Attendance was also much lower among women with a recent  
low-grade abnormality, whose first follow-up test was negative. Attendance was much 
lower than that observed after other recommendations to return in 12 months, and this was 
not explained by laboratory recommendations. It is possible that women may interpret this 
recommendation differently after a negative test than they do after an abnormal test result. 
Overall, laboratory recommendation codes were broadly concordant with the changed 
management guidelines, although concordance was lower for low-grade management 
exceptions (that is, women over 30 and those who had a second low-grade abnormality). 
Evidence showed that the use of automated decision support tools had assisted laboratories 
in complying with the new guidelines. 
This report highlights the importance of monitoring the safety of newly introduced 
guidelines and of having a strong evidence base to assess this. The changes made to the 
NHMRC Guidelines were based on such evidence, but it is not always possible to predict 
what will happen once changes are implemented in a ‘real-world’ environment. It is also 
possible that evidence current at one point in time may no longer be relevant, due to the 
changing nature of the cervical screening environment. Thus it has been critical that safety 
monitoring of key changes to the guidelines continued over a sufficient length of time to 
adequately assure the Safety Monitoring Committee that the available evidence was sound, 
and to be confident in the conclusions drawn from this evidence. 
The AIHW supports monitoring of cervical screening data through performance indicators 
published annually in Cervical screening in Australia reports. Some continuing measures of 
safety monitoring will be included in these reports from 2011–2012 onwards. These measures 
will monitor the safety of women with a low-grade squamous intraepithelial lesion detection 
on cytology, and the safety of women who have completed ‘test of cure’. If at any time in the 
future it becomes apparent that the safety of women is in doubt, timely evidence will exist to 
inform clinicians, policy makers and other key stakeholders, and direct future changes to 
best clinical practice in the prevention of cervical cancer in Australia. 
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Appendix A Additional tables 
Table A.1: Incidence of cervical cancer, 1982 to 2009 
 New cases  AS rate 
Year of diagnosis 20–69 All ages  20–69 All ages 
1982 826 963  19.0 14.2 
1983 841 994  19.0 14.3 
1984 834 1007  18.4 14.2 
1985 896 1058  19.5 14.6 
1986 861 1019  18.6 13.9 
1987 904 1098  18.6 14.4 
1988 900 1065  18.1 13.6 
1989 908 1072  18.0 13.5 
1990 918 1088  18.0 13.5 
1991 895 1094  17.2 13.3 
1992 848 1027  16.0 12.2 
1993 848 1016  15.9 11.9 
1994 936 1143  17.0 13.1 
1995 777 962  13.9 10.7 
1996 759 939  13.4 10.3 
1997 658 809  11.4 8.7 
1998 701 873  11.9 9.2 
1999 661 800  11.0 8.3 
2000 598 769  9.9 7.8 
2001 588 742  9.5 7.4 
2002 560 691  8.9 6.8 
2003 579 730  9.1 7.1 
2004 585 727  9.1 6.9 
2005 607 737  9.3 6.9 
2006 588 719  8.8 6.7 
2007 624 752  9.2 6.9 
2008 641 780  9.3 7.0 
2009 631 771  8.9 6.7 
Note: Age-standardised rate is the number of new cases of cervical cancer per 100,000 women, age-standardised to the Australian population at 
30 June 2001. 
Source: AIHW 2013. 
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Table A.2: Incidence of carcinoma of the cervix (squamous cell carcinoma, adenocarcinoma, 
adenosquamous carcinoma and other carcinoma) in women aged 20–69, 1982 to 2008 
 New cases  AS rate 
Year of 
diagnosis SSC(a) AC(b) ASC(c) Other(d) 
 
SSC(a) AC(b) ASC(c) Other(d) 
1982 656 92 22 35  15.1 2.1 0.5 0.8 
1983 662 83 23 56  15.1 1.9 0.5 1.2 
1984 632 87 44 49  13.9 1.9 1.0 1.1 
1985 689 95 35 54  15.1 2.0 0.8 1.1 
1986 645 117 42 40  13.9 2.5 1.0 0.8 
1987 682 132 41 33  14.0 2.7 0.9 0.7 
1988 651 156 40 40  13.1 3.1 0.8 0.8 
1989 691 111 50 48  13.8 2.2 1.0 0.9 
1990 642 146 49 62  12.6 2.8 1.0 1.2 
1991 647 144 41 56  12.4 2.8 0.8 1.1 
1992 615 137 50 37  11.6 2.6 1.0 0.7 
1993 595 143 48 52  11.2 2.6 0.9 1.0 
1994 640 203 40 49  11.7 3.7 0.7 0.9 
1995 545 146 34 42  9.8 2.6 0.6 0.8 
1996 529 148 40 33  9.4 2.6 0.7 0.6 
1997 454 130 33 31  7.9 2.2 0.6 0.5 
1998 493 141 30 29  8.4 2.4 0.5 0.5 
1999 470 134 23 26  7.9 2.2 0.4 0.4 
2000 403 118 30 27  6.7 1.9 0.5 0.4 
2001 400 115 32 27  6.5 1.9 0.5 0.4 
2002 388 126 18 21  6.2 2.0 0.3 0.3 
2003 397 121 25 26  6.2 1.9 0.4 0.4 
2004 392 133 27 23  6.1 2.1 0.4 0.4 
2005 399 131 20 39  6.1 2.0 0.3 0.6 
2006 366 142 22 38  5.5 2.1 0.3 0.6 
2007 394 157 24 38  5.8 2.3 0.4 0.6 
2008 419 164 21 26  6.1 2.4 0.3 0.4 
(a) SSC = squamous cell carcinoma. 
(b) AC = adenocarcinoma. 
(c) ASC = adenosquamous carcinoma. 
(d) Other = other and unspecified carcinoma. 
Note: Age-standardised (AS) rate is the number of new cases of squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma and 
other carcinomas per 100,000 women, age-standardised to the Australian population at 30 June 2001; rates based on less than 20 new cases 
should be interpreted with caution. 
Source: AIHW 2013. 
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Appendix B Data sources 
Data sources 
Data used in this report are derived from multiple sources and are summarised below.  
Table B.1: Data sources for projects included in this report 
Project Data source 
Background trends in cervical abnormalities and cancer Cervical screening in Australia 2010–2011 (AIHW 
2013) 
State and territory cancer registers 
Risk of cervical cancer in women with low-grade cervical cytology State and territory cervical cytology registers 
Outcomes in women who have attempted ‘test of cure’ State and territory cervical cytology registers 
Cervical cancer case review State and territory cervical cytology registers 
Laboratory survey Pathology laboratories 
Compliance study Victorian cervical cytology register 
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Appendix C Data quality statement:  
Cervical screening safety monitoring data 
Summary of key issues 
• All states and territories maintain a population-based cervical cytology register (also 
referred to as ’Pap test registers’ or ‘Pap smear registers’) to which all cervical cytology, 
histology, and human papillomavirus (HPV) DNA tests are reported. 
• State and territory cervical cytology registers were established to support the National 
Cervical Screening Program (NCSP) that commenced in 1991. 
• The AIHW receives unit record level cervical screening safety monitoring data from state 
and territory cervical cytology registers to allow safety monitoring analyses. 
• Some duplication may occur where the same test data are reported to the cervical 
cytology register in two or more jurisdictions. The AIHW is unable to identify or resolve 
these instances, and the level of duplication is unknown, but believed to be small. 
• Cervical cytology databases change every day, adding new records and improving the 
quality of existing records as new information becomes available. 
Description  
All states and territories have legislation that requires pathology laboratories to send a copy 
of all cervical test results (unless the patient to whom the test belongs objects to its inclusion 
in the register) to the relevant state or territory population-based cervical cytology register. 
Cervical screening programs in each state and territory interrogate their own cervical 
cytology register in accordance with detailed data specifications to supply unit record level 
data to the AIHW. These data are compiled into a database.  
Institutional environment 
The AIHW is a major national agency set up by the Australian Government under the 
Australian Institute of Health and Welfare Act 1987 to provide reliable, regular and relevant 
information and statistics on Australia’s health and welfare. It is an independent statutory 
authority established in 1987, governed by a management Board, and accountable to the 
Australian Parliament through the Health and Ageing portfolio. 
The AIHW aims to improve the health and wellbeing of Australians through better health 
and welfare information and statistics. It collects and reports information on a wide range of 
topics and issues, ranging from health and welfare expenditure, hospitals, disease and 
injury, and mental health, to ageing, homelessness, disability and child protection. 
The Institute also plays a role in developing and maintaining national metadata standards. 
This work contributes to improving the quality and consistency of national health and 
welfare statistics. The Institute works closely with governments and non-government 
organisations to achieve greater adherence to these standards in administrative data 
collections to promote national consistency and comparability of data and reporting. 
One of the main functions of the AIHW is to work with the states and territories to improve 
the quality of administrative data and, where possible, to compile national data sets based on 
data from each jurisdiction, to analyse these data sets and disseminate information and 
statistics. 
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The Australian Institute of Health and Welfare Act 1987, in conjunction with compliance to the 
Privacy Act 1988 (Cwth), ensures that the data collections managed by the AIHW are kept 
securely and under the strictest conditions with respect to privacy and confidentiality. 
For further information see the AIHW website <www.aihw.gov.au>. 
The AIHW has been receiving cervical screening safety monitoring data since 2008.  
Timeliness 
Cervical cytology data are available within about 6 months (there can be a lag of up to 6 
months in the transmission of test results from pathology laboratories to cervical cytology 
registers), and data for the previous calendar year are supplied in July. 
The current cervical screening safety monitoring data contains all low-grade cytology and 
high-grade histology tests performed and reported to the cervical cytology registers from 
1 January 2007 to 31 December 2012.  
Accessibility 
Cervical screening safety monitoring data appear for the first time in Report on the activity of 
the National Cervical Screening Program, and are thereafter published annually in the report 
Cervical screening in Australia, as of the 2011–2012 report, available on the AIHW website 
<http://www.aihw.gov.au/cervical-cancer-screening/> where they can be downloaded 
without charge. 
General enquiries about AIHW publications can be made to the Media and Strategic 
Engagement Unit on (02) 6244 1032 or via email to <info@aihw.gov.au>.  
Interpretability 
While many concepts are easy to interpret, other concepts and statistical calculations are 
more complex and may be confusing to some users. All concepts are explained within the 
body of the report presenting these data, along with footnotes to provide further details. 
Relevance 
Cervical screening safety monitoring data are highly relevant for monitoring the safety of the 
NHMRC Guidelines. The data are used for many purposes by policy-makers and 
researchers, but are supplied and analysed specifically to monitor and inform the SMC in 
this forum. 
Accuracy 
All data provided by state and territory cervical screening programs, once analysed, are 
verified to ensure accuracy. 
Coherence 
Cervical screening safety monitoring data are reported and published annually by the AIHW 
from 2014. 
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Appendix D Statistical methods 
Data rules 
Data on deaths and cervical cancer diagnoses were gained from the state and territory 
cervical cytology registers. 
As date of death data were only available by year, deaths were assumed to occur on 30th 
June of that year, unless a woman died in the same year as her most recent test. It was then 
assumed that the date of death was half-way between the date of the most recent test and the 
end of the year. 
Cancer histology and high-grade histology results provided to the AIHW were mapped to 
their respective categories according to the National Cervical Cancer Prevention Dataset, 
developed in discussion with the state and territory cervical cytology registers. 
Age groups used to check for age-specific differences within cohorts were 20–29, 30–49 and 
50–69 for Parameter 1, and 20–39 and 40–69 for Parameter 2. 
Methods 
Safety monitoring parameters 
The method of measuring incidence of cervical cancer within 2 years of an index low-grade 
cytology test used in this paper was the person-time approach. Follow-up time is calculated 
from any low-grade cytology test in the reference period, and is stopped (censored) at event 
of cancer, end of reference period (or 5 years) or death.  
Crude rates 
A crude rate is defined as the number of events over a specified period of time (for example, 
a year) divided by the total population. For example, a crude cancer incidence rate is defined 
as the number of new cases of cancer in a specified period of time divided by the population 
at risk. 
Age-standardised rates (AS rates) 
Rates are adjusted for age to facilitate comparisons between populations that have different 
age structures, for example, between youthful and ageing communities. There are two 
different methods commonly used to adjust for age. In this publication, we use direct 
standardisation in which age-specific rates are multiplied against a constant population (the 
2001 Australian Standard Population unless otherwise specified). This effectively removes 
the influence of age structure on the summary rate, described as the age-standardised rate.  
The method used for this calculation comprises three steps: 
• Calculate the age-specific rate (as shown above) for each age group. 
• Calculate the expected number of cases in each 5-year age group by multiplying the  
age-specific rates by the corresponding standard population and dividing by the 
appropriate factor (for example, per 100,000 women). 
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• To give the age-standardised rate, sum the expected number of cases in each group, 
divide by the total of the standard population and multiply by the appropriate factor (for 
example, per 100,000 women). 
Confidence intervals 
Population numbers for incidence and screening have a natural level of variability for a 
single year above and below what might be expected in the mean over many years. The 
percentage variability is small for large population numbers but high for small numbers such 
as incidence in a young age group. One measure of the likely difference is the standard error, 
which indicates the extent to which a population number might have varied by chance in 
only 1 year of data. 
The 95% confidence intervals presented in this paper were calculated using a method 
developed by Dobson et al. (1991) and assumed that incidence and screening counts were 
Poisson random variables. For an observed count, based on data from a single year, there are 
19 chances in 20 that the associated confidence interval contains the corresponding annual 
average (for several years).  
Kaplan-Meier estimates (cumulative incidence curves) 
Kaplan-Meier methods are standard methods used to estimate the frequency distribution (or 
incidence curve) of an event over time. In this paper, the method estimates the probability of 
cervical cancer for each week from the date of an abnormality finding. The Kaplan-Meier 
estimate is a function of both the weekly and cumulative incidence rates. 
Separate incidence curves are calculated for the baseline and ongoing cohorts and the log-
rank statistic is used to determine whether the two distributions are significantly different. 
This shows whether or not there is a statistically significant difference in the rate of 
progression to cancer (following an abnormality) associated with the change in guidelines.  
Proportional hazard regression rates 
Proportional hazards regression allows the analysis of the effect of several risk factors on 
survival, or in this case, cervical cancer diagnosis. Proportional hazard regression modelling 
was used to estimate the ratio of the likelihood of cancer diagnosis for the ongoing cohort to 
that for the baseline cohort. Specifically, time to diagnosis was modelled as a function of a 
random variable indicating the cohort to which an individual belongs; value zero was 
assigned to the baseline cohort and value one to the ongoing cohort. The estimated 
regression coefficient was interpreted as this ratio in the chance of diagnosis. This 
interpretation relies on the ‘proportional hazards’ assumption that the probability of 
diagnosis within the ongoing cohort, relative to that in the baseline cohort, is constant over 
time.  
Mantel-Haenszel rate ratios 
Mantel-Haenszel methods allow for the stratified analysis of the relationship between two 
groups, after controlling for various confounding factors. This method is generally valid for 
small-moderate samples sizes; however, zero values within individual strata may affect 
validity. 
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Sequential monitoring 
We perform a two-sided test of the hypothesis that the hazard ratio (of the ongoing to the 
baseline cohort) is equal to one, or equivalently, that the logarithm of the hazard ratio is zero.  
The test statistic is calculated with the following formula: 
  
[ ]
[ ][ ]ratiohazardSE
ratiohazard
log
log
. 
In a non-sequential experiment we would reject the null hypothesis (that there is no 
difference) if the value of this statistic exceeds 1.96 (critical value at the 5% -level). 
However, in analysis of the sequential Safety Monitoring data the critical value of 1.96 is 
replaced by the Wang and Tsiatis (1987) values for eight monitoring points.  
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the National Cervical Screening Program 
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This report looks at the evidence collected and assessed 
by the safety Monitoring Committee established to 
assess whether there were adverse outcomes following 
the introduction of new nHMrC guidelines on how 
women with a low-grade Pap test result or a treated 
high-grade cervical biopsy result should be managed. 
acknowledging that new evidence may come to light in 
future which could affect this picture, the overarching 
message from the evidence currently available and the 
methods used to assess this evidence is that the new 
guidelines have not led to an increase in cervical cancer 
in the seven years since they were introduced.
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